Medicinal chemistry of Hsp90 inhibitors

Current Topics in Medicinal Chemistry

Volumn 8, Issue 10, 2008, Pages 859-868

  Drysdale, Martin J ^a   Brough, Paul A ^a  

^a Vernalis PLC   (United Kingdom)

Author keywords

Anti cancer; Hsp90; Structure based design

Indexed keywords

17 DIMETHYLAMINOETHYLGELDANAMYCIN; 3 (5 CHLORO 2,4 DIHYDROXYPHENYL) N ETHYL 4 (4 METHOXYPHENYL) 5 PYRAZOLECARBOXAMIDE; 4 [4 (1,4 BENZODIOXAN 6 YL) 5 METHYL 1H PYRAZOL 3 YL] 6 ETHYLRESORCINOL; 4 PIPERAZINYL DERIVATIE; 6 CHLOROPURINE DERIVATIVE; ARYLSUFANYL DERIVATIVE; ARYLSUFINYL DERIVATIVE; ARYLSUFONYL DERIVATIVE; BENZOTHIAZOLOTHIOPURINE DERIVATIE; BIIB 021; CYCLOPROPARADICICOL; G 3129; G 3130; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; KF 58333; NATURAL PRODUCT; NVP AUY 922; POCHONIN A; POCHONIN D; PYRIDINOTHIAZOLOTHIOPURINE DERIVATIE; RADANAMYCIN; RADESTER; RADICICOL; RESORCINOL; TANESPIMYCIN; VER 50589; VER 52296;

AREA UNDER THE CURVE; CELL STRAIN MCF 7; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IC 50; LIVER MICROSOME; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR WEIGHT; NONHUMAN; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; MOLECULAR STRUCTURE; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 47249153969     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802608784911644     Document Type: Review

References (73)

1. Mosser, D. D. and Morimoto, R. I. Molecular chaperones and the stress of oncogenesis. Oncogene 2004, 23, 2907-2918.
2. Hanahan, D. and Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
3. DeBoer, C.; Meulman, P. A.; Wnuk, R. J.; and Peterson, D. H. Geldanamycin, a new antibiotic. J. Antibiot. (Tokyo) 1970, 23, 442-447.
4. Supko, J. G.; Hickman, R. L.; Grever, M. R.; and Malspeis, L. Preclinical pharmacologic evaluation of geldenamycin as an antitumor agent. Cancer Chemother. Pharmacol. 1995, 36, 305-315.
5. Neckers, L.; Schulte, T. W.; and Mimnaugh, E. Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity. Invest New Drugs 1999, 17, 361-373.
6. Delmotte, P. and Delmotte-Plaque, J. A new antifungal substance of fungal origin. Nature 1953, 171, 344.
7. Soga, S.; Shiotsu, Y.; Akinaga, S.; and Sharma, S. V. Development of radicicol analogues. Curr. Cancer Drug Targets 2003, 3, 359-369.
8. Maloney, A. and Workman, P. RSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert. Opin. Biol. Ther. 2002, 2, 3-24.
9. Isaacs, J. S.; Xu, W.; and Neckers, L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3, 213-217.
10. Workman, P. Altered states: Selectively drugging die Hsp90 cancer chaperone. Trends Mol. Med. 2004, 10, 47-51.
11. Dymock, B. W.; Drysdale, M. J.;, McDonald, E.; and Workman, P. Inhibitors of HSP90 and other chaperones for the treatment of cancer. Expert Opin. Ther. Pat. 2004, 14, 837-847.
12. Chiosis, G.; Vilenchik, M.; Kim, J.; and Solit, D. Hsp90: The vulnerable chaperone. Drug Discov. Today 2004, 9, 881-888.
13. Whitesell, L. and Lindquist, S. L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5, 761-772.
14. Janin, Y. L. Heat shock protein 90 inhibitors. A text book example of medicinal chemistry? J. Med. Chem. 2005, 48, 7503-7512.
15. Chiosis, G.; Rodina, A.; and Moulick, K. Emerging Hsp90 inhibitors: From discovery to clinic. Anticancer Agents Med. Chem. 2006, 6, 1-8.
16. Chiosis, G. Targeting chaperones in transformed systems - a focus on Hsp90 and cancer. Expert. Opin. Ther. Targets 2006, 10, 37-50.
17. Kamal, A.; Boehm, M. F.; and Burrows, F. J. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med. 2004, 10, 283-290.
18. Neckers, L. and Neckers, K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert. Opin. Emerg. Drugs 2005, 10, 137-149.
19. Drysdale, M. J.; Brough, P. A.; Massey, A.; Jensen, M. R.; and Schoepfer, J. Targeting Hsp90 for the treatment of cancer. Curr. Opin. Drug Discov. Devel. 2006, 9, 483-495.
20. McDonald, E.; Workman, P.; and Jones, K. Inhibitors of the HSP90 molecular chaperone: Attacking the master regulator in cancer. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2006, 6, 1091-1107.
21. McDonald, E.; Jones, K.; Brough, P. A.; Drysdale, M. J.; and Workman, P. Discovery and development of pyrazole-scaffold Hsp90 inhibitors. Curr. Top. Med. Chem. 2006, 6, 1193-1203.
22. Powers, M. V. and Workman, P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr. -Relat. Cancer 2006, 13, S125-S135.
23. Chiosis, G.; Caldas, L. E.; and Solit, D. Heat shock protein-90 inhibitors: A chronicle from geldanamycin to today's agents. Curr. Opin. Investig. Drugs 2006, 7, 534-541.
24. Xu, W. and Neckers, L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin. Cancer Res. 2007, 13, 1625-1629.
25. Workman, P.; Burrows, F.; Neckers, L.; and Rosen, N. Drugging the cancer chaperone HSP90: Combinatorial therapeutic expolitation on oncogene addiction and tumor stress. Ann. N. Y. Acad. Sci. 2007, 1113, 202-216.
26. Pearl, L. H.; Prodromou, C.; and Workman, P. The Hsp90 molecular chaperone: An open and shut case for treatment. Biochem. J. 2008, 410, 439-453.
27. Chiosis, G.; Kang, Y.; and Sun, W. Discovery and development of purine-scaffold Hsp90 inhibitors. Expert Opin. Drug Discov. 2008, 3, 99-114.
28. Schulte, T. W. and Neckers, L. M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 1998, 42, 273-279.
29. Banerji, U.; O'Donnell, A.; Scurr, M.; Pacey, S.; Stapleton, S.; Asad, Y.; Simmons, L.; Maloney, A.; Raynaud, F.; Campbell, M.; Walton, M.; Lakhani, S.; Kaye, S.; Workman, P.; and Judson, I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 2005, 23, 4152-4161.
30. Goetz, M. P.; Toft, D.; Reid, J.; Ames, M.; Stensgard, B.; Safgren, S.; Adjei, A. A.; Sloan, J.; Atherton, P.; Vasile, V.; Salazaar, S.; Adjei, A.; Croghan, G.; and Erlichman, C. Phase I trial of 17-allylamino-17-demethoxygeldanamcin in patients with advanced cancer. J. Clin. Oncol. 2005, 23, 1078-1087.
31. Weigel, B. J.; Blaney, S. M.; Reid, J. M.; Safgren, S. L.; Bagatell, R.; Kersey, J.; Neglia, J. P.; Ivy, S. P.; Ingle, A. M.; Whitesell, L.; Gilbertson, R. J.; Krailo, M.; Ames, M.; and Adamson, P. C. A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study. Clin. Cancer Res. 2007, 13, 1789-1793.
32. Modi, S.; Stopeck, A. T.; Gordon, M. S.; Mendelson, D.; Solit, D. B.; Bagatell, R.; Ma, W.; Wheler, J.; Rosen, N.; Norton, L.; Cropp, G. F.; Johnson, R. G.; Hannah, A, L.; and Hudis, C. A. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER2-overexpressing breast cancer a phase I dose-escalation study. J. Clin. Oncol. 2007, 25, 5410-5417.
33. Egorin, M. J.; Rosen, D. M.; Wolff, J. H.; Callery, P. S.; Musser, S. M.; and Eiseman, J. L. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res. 1998, 58, 2385-2396.
34. Kelland, L. R.; Sharp, S. Y.; Rogers, P. M.; Myers, T. G.; and Workman, P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. 1999, 91, 1940-1949.
35. Kaur, G.; Belotti, D.; Burger, A. M.; Fisher-Nielson, K.; Borsotti, P.; Riccardi, E.; Thillainathan, J.; Hollingshead, M.; Sausville, E. A.; and Giavazzi, R. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: An orally bioavailable heat shock protein 90 modulator. Clin. Cancer Res. 2004, 10, 4813-4821.
36. Ge, J.; Normant, E.; Porter, J. R.; Ali, J. A.; Dembski M. S.; Gao, Y.; Georges, A. T.; Grenier, L.; Pak, R. H.; Patterson, J.; Sydor, J. R.; Tibbitts, T. T.; Tong, J. K.; Adams, J.; and Palombella, V. J. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J. Med. Chem. 2006, 49, 4606-4615.
37. Sydor, J. R.; Normant, E.; Pien, C. S.; Porter, J. R.; Ge, J.; Grenier, L.; Pak, R. H.; Ali, J. A.; Dembski M. S.; Hudak, J.; Patterson, J.; Penders, C.; Pink, M.; Read, M. A.; Sang, J.; Woodward, C.; Zhang, Y.; Grayzel, D. S.; Wright; J.; Barren, J. A.; Palombella, V. J.; Adams, J.; and Tong, J. K. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc. Natl. Acad. Sci. USA 2006, 103, 17408-17413.
38. Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, P. N.; Zheng, F. F.; Sepp-Lorenzino, L.; and Rosen, N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 2001, 8, 289-299.
39. Dymock, B.; Barril, X.; Beswick, M.; Collier, A.; Davies, N.; Drysdale, M.; Fink, A.; Fromont, C.; Hubbard, R. E.; Massey, A.; Surgenor, A.; and Wright, L. Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures. Bioorg. Med. Chem. Lett. 2004, 14, 325-328.
40. Wright, L.; Barril, X; Dymock, B.; Sheridan, L.; Surgenor, A.; Beswick, M.; Drysdale, M.; Collier, A.; Massey, A.; Davies, N.; Fink, A.; Fromont, C.; Aherne, W.; Boxall, K.; Sharp, S.; Workman, P.; and Hubbard, R. E. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem. Biol. 2004, 11, 775-785.
41. Howes, R.; Barril, X.; Dymock, B. W.; Grant K.; Northfield, C. J.; Robertson, A. G.; Surgenor, A.; Wayne, J.; Wright; L.; James, K.; Matthews, T.; Cheung, K. M.; McDonald, E.; Workman, P.; and Drysdale, M. J. A fluorescence polarization amy for inhibitors of Hsp90. Anal. Biochem. 2006, 350, 202-213.
42. Lucas, B.; Rosen, N.; and Chiosis, G. Facile synthesis of a library of 9-alkyl-8-benzyl-9H-purin-6-ylamine derivatives. J. Comb. Chem. 2001, 3, 518-520.
43. Chiosis, G.; Lucas, B.; Shtil, A.; Huezo, H.; and Rosen, N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg. Med. Chem. 2002, 10, 3555-3564.
44. Vilenchik, M.; Solit, D.; Basso, A.; Huezo, H.; Lucas, B.; He, H.; Rosen, N.; Spampinato, C.; Modrich, P.; and Chiosis, G. Targeting wide-range oncogenic transformation via PU24FCL a specific inhibitor of tumor Hsp90. Chem Biol. 2004, 11, 787-797.
45. Llauger, L.; He, H.; Kim, J.; Aguirre, J.; Rosen, N.; Peters, U.; Davies, P.; and Chiosis, G. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J. Med. Chem. 2005, 48, 2892-2905.
46. He, H.; Zatorska, D.; Kim, J.; Aguirre, J.; Llauger, L.; She, Y.; Wu, N.; Immormino, R, M.; Gewirth, D. T.; and Chiosis, G. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J. Med. Chem. 2006, 49, 381-390.
47. Biamonte, M. A.; Shi, J.; Hong, K.; Hurst, D. C.; Zhang, L.; Fan, J.; Busch, D. J.; Kaijian, P. L.; Maldonado, A. A.; Sensintaffar, J. L.; Yang, Y. C.; Kamal, A.; Lough, R. E.; Lundgren, K.; Burrows, F. J.; Timony, G. A.; Boehm, M. F.; and Kasibhatla S. R. Orally active purine-based inhibitors of the heat shock protein 90. J. Med. Chem. 2006, 49, 817-828.
48. Zhang, L.; Fan, J.; Vu, K.; Hong, K.; Le Brazidec, J. Y.; Shi, J.; Biamonte, M.; Busch, D. J.; Lough, R. E.; Grecko, R.; Ran, Y.; Sensintaffar, J. L.; Kamal, A.; Lundgren, K.; Burrows, F. J.; Mansfield, R.; Timony, G. A.; Ulm, E. H.; Kasibhatla S. R.; and Boehm, M. F. 7′-Substituted benzothiazolothio- and pyridinothia-zolothio-purines as potent heat shock protein 90 inhibitors. J. Med. Chem. 2006, 49, 5352-5362.
49. Kasibhata, U S. R.; Hong, K.; Biamonte, M. A.; Busch, D. J.; Karjian, P. L.; Sensintaffar, J. L.; Kamal A.; Lough, R. E.; Brekken, J.; Lundgren, K.; Grecko, R.; Timony, G. A.; Ran, Y.; Mansfield, R.; Fritz, L. C.; Ulm, E.; Burrows, F. J.; and Boehm, M. F. Rationally designed higl-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. J. Med. Chem. 2007, 50, 2767-2778.
50. Lundgren, K.; Zhang, H.; Kamal, A.; Lough, R.; Timple, N.; Sensintaffar, J.; Busch, D. J.; Yang, C.; Neely, L.; Khan, S.; Hong, K.; Kasibhatla, S.; Boehm, M. F.; and Burrows, F. BIIB021 is a small molecule inhibitor of the heat shock protein, Hsp90, that hows potent anti-tumor activity in preclinical. models. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, 22-26 October, 2007.
51. Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; and Pearl, L. H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 1999, 42, 260-266.
52. Yamamoto, K; Garbaccio, R. M.; Stachel, S. J.; Solit, D. B.; Chiosis, G.; Rosen, N.; and Danishefisky, S. J. Total synthesis as a resource in the discovery of potentially valuable antitumor agents: cycloproparadicicol. Angew. Chem. Int. Ed Engl. 2003, 42, 1280-1284.
53. Yang, Z. Q.; Geng, X; Solit, D.; Pratilas, C. A.; Rosen, N.; and Danishefsky, S. J. New efficient synthesis of resorcinylic macrolides via ynolides: Establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target. J. Am. Chem. Soc. 2004, 126, 7881-7889.
54. Soga, S.; Neckers, L. M.; Schulte, T., W.; Shiotsu, Y.; Akasaka, K.; Narumi, H.; Agatsuma, T.; Ikuina, Y.; Murakata, C.; Tamaoki, T.; and Akinaga, S. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res. 1999, 59, 2931-2938.
55. Shiotsu, Y.; Neckers, L. M.; Wortman, I.; An, W. G.; Schulte, T. W.; Soga, S.; Murakata, C.; Tamaoki, T.; and Akinaga, S. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Ab1 with Hsp90 complex. Blood 2000, 96, 2284-2291.
56. Atrash, B.; Cooper, T. S.; Sheldrake, P.; Workman, P.; and McDonald, E. Development of synthetic routes to macrocyclic compounds based on the HSP90 inhibitor radicicol. Tetrahedron Lett., 2006, 47, 2237-2240.
57. Cooper, T. S.; Atrash, B.; Sheldrake, P.; Workman, P.; and McDonald, E. Synthesis of resorcinylic macrocycles related to radicicol via ring-closing metathesis. Tetrahedron Lett. 2006, 47, 2241-2243.
58. Shen, G. and Blagg, B. S. Radester, a novel inhibitor of the Hsp90 protein folding machinery. Org. Lett. 2005, 7, 2157-2160.
59. Wang, M.; Shen, G.; and Blagg, B. S. Radanamycin, a macrocyclic chimera of radicicol and geldanamycin. Bioorg. Med. Chem. Lett. 2006, 16, 2459-2462.
60. Moulin, E.; Zoete, V.; Barluenga, S.; Karplus, M.; and Winssinger, N. Design, synthesis, and biological evaluation of HSP90 inhibitors based on conformational analysis of radicicol and its analogues. J. Am Chem. Soc. 2005, 127, 6999-7004.
61. Moulin, E.; Barluenga, S.; and Wingsinger, N. Concise synthesis of pochonin A, an HSP90 inhibitor. Org. Lett. 2005, 7, 5637-5639.
62. Cheung, K. M.; Matthews, T. P.; James, K.; Rowlands, M. G.; Boxall, K. J.; Sharp, S. Y.; Malonn A.; Roe, S. M.; Prodromou, C.; Pearl, L. H.; Aherne, G. W.; McDonald, E.; and Workman, P. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg. Med. Chem Lett. 2005, 15, 3338-3343.
63. Kreusch, A.; Han, S.; Brinker, A.; Zhou, V.; Choi, H. S.; He, Y.; Lesley, S. A.; Caldwell, J.; and Gu, X. J. Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles. Bioorg. Med. Chem. Lett. 2005, 15, 1475-1478.
64. Gopalsamy, A.; Shi, M.; Golas, J.; Vogan, E.; Jacob, J.; Johnson, M.; Lee, F.; Nilakantan, R.; Petersen, R.; Svenson, K.; Chopra, R.; Tam, M. S.; Wen, Y.; Ellingboe, J.; Arndt, K.; and Boschelli, F. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90. J. Med. Chem. 2008, 51, 373-375.
65. Dymock, B. W.; Barril, X.; Brough, P. A.; Cansfield, J. E.; Massey, A.; McDonald, E.; Hubbard, R. E.; Surgenor, A.; Roughley, S. D.; Webb, P.; Workman P.; Wright, L.; and Drysdale, M. J. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J. Med Chem. 2005, 48, 4212-4215.
66. Brough, P. A.; Barril, X.; Beswick, M.; Dymock, B. W.; Drysdale, M. J.; Wright, L.; Grant, K.; Massey, A.; Surgenor, A.; and Workman, P. 3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone. Bioorg. Med. Chem. Lett. 2005, 15, 5197-5201.
67. Barril, X.; Beswick, M. C.; Collier, A.; Drysdale, M. J.; Dymock, B. W.; Fink, A.; Grant, K.; Howes, R.; Jordan, A. M.; Massey, A.; Surgenor, A.; Wayne, J.; Workman, P.; and Wright, L. 4-Amino derivatives of the Hsp9O inhibitor CCT018159. Bioorg. Med. Chem. Lett. 2006, 16, 2543-2548.
68. Brough, P. A.; Aherne, W.; Barril, X.; Borgognoni, J.; Boxall, K.; Cansfield, J. E.; Cheung, K. M.; Collins, I.; Davies, N. G.; Drysdale, M. J.; Dymock, B.; Eccles, S. A.; Finch, H.; Fink, A.; Hayes, A.; Howes, R.; Hubbard, R. E.; James, K.; Jordan, A. M.; Lockie, A.; Martins, V.; Massey, A.; Matthews, T. P.; McDonald, E.; Northfield, C. J.; Pearl, L. H.; Prodromou, C.; Ray, S.; Raynaud, F. I.; Roughley, S. D.; Sharp, S. Y.; Surgenor, A.; Walmsley, D. L.; Webb, P.; Wood, M.; Workman, P.; and Wright, L. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer. J. Med. Chem. 2008, 51, 196-218.
69. Sharp, S. Y.; Prodromou, C.; Boxall, K.; Powers, M. V.; Holmes, J. L.; Box, G.; Matthews, T. P.; Cheung, K. M.; Kalusa, A.; James, K.; Hayes. A.; Hardcastle, A.; Dymock, B.; Brough, P. A.; Barril, X.; Cansfield, J. E.; Wright, L.; Surgenor, A.; Foloppe, N.; Hubbard, R. E.; Aherne, W.; Pearl, L.; Jones, K.; McDonald, E.; Raynaud, F.; Eccles, S.; Drysdale, M.; and Workman, P. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol. Cancer Ther. 2007, 6, 1198-1211.
70. Barril; X.; Brough, P.; Drysdale, M.; Hubbard, R. E.; Massey, A.; Surgenor, A.; and Wright, L. Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 5187-5191.
71. Park, H.; Kim, Y. J.; and Hahn, J. S. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening. Bioorg. Med. Chem. Lett. 2007, 17, 6345-6349.
72. Huth, J. R.; Park, C.; Petros, A. M.; Kunzer, A. R.; Wendt, M. D.; Wang, X.; Lynch, C. L.; Mack, J. C.; Swift, K. M.; Judge, R. A.; Chen, J.; Richardson, P. L.; Jin, S.; Tahir, S. K.; Matayoshi, E. D.; Dorwin, S. A.; Ladror, U. S.; Severin, J. M.; Walter, K. A.; Bartley, D. M.; Fesik S. W.; Elmore, S. W.; and Hajduk, P. J. Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies. Chem. Biol. Drug Des. 2007, 70, 1-12.
73. Hubbard, R. E.; Davis, B.; Chen, I.; and Drysdale, M. J. The SeeDs approach: Integrating fragments into drug discovery. Curr. Top. Med. Chem., (Sharjah, United Arab Emirates) 2007, 7, 1568-1581.